Editorial
Current opportunities and challenges in ALK-positive lung cancer
Translational Lung Cancer Research
2024;
13
(1)
:1-4
.
(31 January 2024)
Original Article
Expression of cytokines in pleural effusions and corresponding cell lines of small cell lung cancer
Translational Lung Cancer Research
2024;
13
(1)
:5-15
.
(31 January 2024)
Prognostic factors of resectable anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) patients: a retrospective analysis based on a single center
Translational Lung Cancer Research
2024;
13
(1)
:16-33
.
(31 January 2024)
In-depth proteomic analysis identifies key gene signatures predicting therapeutic efficacy of anti-PD-1/PD-L1 monotherapy in non-small cell lung cancer
Translational Lung Cancer Research
2024;
13
(1)
:34-45
.
(31 January 2024)
Clinical and financial impact of immune checkpoint inhibitors following platinum chemotherapy in patients with advanced or metastatic non-small cell lung cancer: a nationwide population-based study
Translational Lung Cancer Research
2024;
13
(1)
:46-59
.
(31 January 2024)
Bronchoscopic deployment and implantation of Diffusing alpha-emitters Radiation Therapy into the lung and mediastinum for treatment of lung cancer: a pre-clinical safety and feasibility study
Translational Lung Cancer Research
2024;
13
(1)
:60-75
.
(31 January 2024)
Racial disparities in staging, treatment, and mortality in non-small cell lung cancer
Translational Lung Cancer Research
2024;
13
(1)
:76-94
.
(31 January 2024)
Nomogram for predicting prognosis and identifying chemotherapy beneficiaries for completely resected stage I invasive mucinous lung adenocarcinoma
Translational Lung Cancer Research
2024;
13
(1)
:95-111
.
(31 January 2024)
Machine learning model for circulating tumor DNA detection in chronic obstructive pulmonary disease patients with lung cancer
Translational Lung Cancer Research
2024;
13
(1)
:112-125
.
(31 January 2024)
Potential synergistic effects of cranial radiotherapy and atezolizumab in non-small cell lung cancer: an analysis of individual patient data from seven prospective trials
Translational Lung Cancer Research
2024;
13
(1)
:126-138
.
(31 January 2024)
Real-world incidence and risk factors of pneumonitis in chemoradiation plus immune checkpoint inhibitors compared with chemoradiation alone in lung cancer: a retrospective cohort study
Translational Lung Cancer Research
2024;
13
(1)
:139-151
.
(31 January 2024)
Alectinib continuation beyond progression in ALK-positive non-small cell lung cancer with alectinib-refractory
Translational Lung Cancer Research
2024;
13
(1)
:152-162
.
(31 January 2024)
Review Article
Lung cancer in females—sex-based differences from males in epidemiology, biology, and outcomes: a narrative review
Translational Lung Cancer Research
2024;
13
(1)
:163-178
.
(31 January 2024)
Case Report
Non-bacterial thrombotic endocarditis in ROS1-rearranged lung cancer: a report of two cases
Translational Lung Cancer Research
2024;
13
(1)
:179-185
.
(31 January 2024)
Editorial Commentary
PD-1 expression on tumor cells: a new target for cancer therapy
Translational Lung Cancer Research
2024;
13
(1)
:186-189
.
(31 January 2024)
Role of CDK4/6 inhibitors in targeting Rb proficient small cell lung cancer
Translational Lung Cancer Research
2024;
13
(1)
:190-194
.
(31 January 2024)
Subtype of EGFR exon 19 deletion mutations
Translational Lung Cancer Research
2024;
13
(1)
:195-198
.
(31 January 2024)
PI4K2A: a novel potential therapeutic target for lung cancer
Translational Lung Cancer Research
2024;
13
(1)
:199-204
.
(31 January 2024)
Will perioperative pembrolizumab treatment change perioperative treatment strategies for resectable non-small cell lung cancer?
Translational Lung Cancer Research
2024;
13
(1)
:205-209
.
(31 January 2024)
Letter to the Editor
Biomarkers: a new frontier in lung cancer detection
Translational Lung Cancer Research
2024;
13
(1)
:210-212
.
(31 January 2024)
Biomarkers as a tool to reduce disparities in lung cancer screening and detection
Translational Lung Cancer Research
2024;
13
(1)
:213-214
.
(31 January 2024)
